VAXX Stock Price, Vaxxinity, Inc. Quote, Chart

Market Summary

USD0.120.00

Delayed

0.00%

VAXX Stock Price

View Fullscreen

VAXX RSI Chart

VAXX Valuation

Market Cap

15.2M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

230.02

EV/EBITDA

-0.19

Price/Free Cashflow

-0.26

VAXX Price/Sales (Trailing)

VAXX Profitability

Operating Margin

100.00%

EBT Margin

-86263.64%

Return on Equity

-424.6%

Return on Assets

-128.49%

Free Cashflow Yield

-382.32%

VAXX Fundamentals

VAXX Revenue

Revenue (TTM)

66.0K

VAXX Earnings

Earnings (TTM)

-56.9M

Earnings Growth (Yr)

44.31%

Earnings Growth (Qtr)

13.34%

Breaking Down VAXX Revenue

Last 7 days

-75%

Last 30 days

-82.6%

Last 90 days

-82.3%

Trailing 12 Months

-94.5%

How does VAXX drawdown profile look like?

VAXX Financial Health

Current Ratio

1.89

VAXX Investor Care

Shares Dilution (1Y)

0.45%

Diluted EPS (TTM)

-0.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	434.3K	311.5K	188.8K	66.0K
2020	0	0	0	557.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vaxxinity, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 08, 2023	prime movers lab fund i lp	sold	-7,042	1.67	-4,217	-
Sep 08, 2023	prime movers lab fund i lp	sold	-9,871	1.67	-5,911	-
Sep 08, 2023	prime movers lab fund i lp	sold	-3,999	1.67	-2,395	-
Sep 08, 2023	prime movers lab fund i lp	sold	-17,282	1.67	-10,349	-
Sep 08, 2023	prime movers lab fund i lp	sold	-41,898	1.67	-25,089	-
Sep 07, 2023	prime movers lab fund i lp	sold	-36,301	1.7872	-20,312	-
Sep 07, 2023	prime movers lab fund i lp	sold	-8,553	1.7872	-4,786	-
Sep 07, 2023	prime movers lab fund i lp	sold	-6,099	1.7872	-3,413	-
Sep 07, 2023	prime movers lab fund i lp	sold	-3,465	1.7872	-1,939	-
Sep 07, 2023	prime movers lab fund i lp	sold	-14,973	1.7872	-8,378	-

Which funds bought or sold VAXX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-8.83	-23,629	78,936	-%
Apr 24, 2024	Spire Wealth Management	reduced	-52.68	-7,190	6,458	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	unchanged	-	-1,000	9,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.18	-4,000	1,000	-%
Apr 23, 2024	McAdam, LLC	unchanged	-	-10,372	56,167	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	reduced	-39.61	-7,707	8,014	-%
Apr 18, 2024	Blue Zone Wealth Advisors, LLC	unchanged	-	-5,432	29,418	0.01%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%
Apr 17, 2024	Clarius Group, LLC	unchanged	-	-2,650	14,350	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.57	-1,224,810	2,032,210	-%

Are Funds Buying or Selling VAXX?

Are funds buying VAXX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VAXX

No. of Funds

Unveiling Vaxxinity, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	hu mei mei	70.5%	79,600,421	SC 13G/A
Feb 12, 2024	reese lou	9.4%	10,566,066	SC 13G/A
Feb 07, 2024	prime movers lab fund i lp	1.06%	1,201,994	SC 13G/A
Feb 13, 2023	prime movers lab fund i lp	8.2%	9,169,589	SC 13G/A
Jan 27, 2023	united biomedical inc	51.6%	57,877,859	SC 13G/A
Jan 27, 2023	hu mei mei	69.5%	77,941,198	SC 13G/A
Apr 27, 2022	united biomedical inc	51.6%	57,733,969	SC 13G
Apr 27, 2022	reese lou	8.6%	9,583,211	SC 13G
Apr 27, 2022	hu mei mei	69.5%	77,797,308	SC 13G
Feb 09, 2022	prime movers lab fund i lp	8.7%	9,738,192	SC 13G

Recent SEC filings of Vaxxinity, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	8-K	Current Report
Mar 27, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Feb 15, 2024	8-K	Current Report
Feb 12, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	SC 13G/A	Major Ownership Report
Jan 30, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Vaxxinity, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Vaxxinity, Inc. News

Latest updates

Vaxxinity, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	0%	50,000	50,000	50,000	-	17,000	67,000	117,000
Cost Of Revenue	-	-	-	9,000	1,927,000	1,000	-	-178,000
Gross Profit	100.0%	-	-1,000	41,000	-1,927,000	16,000	-	295,000
Operating Expenses	-63.9%	17,224,000	47,750,000	30,316,000	24,866,000	20,272,000	-	12,989,000
S&GA Expenses	-78.6%	6,560,000	30,608,500	6,873,000	5,846,000	8,584,000	-	5,122,000
R&D Expenses	-37.8%	10,664,000	17,141,500	23,443,000	19,020,000	11,688,000	-	7,867,000
EBITDA Margin	-131.6%	-2,052	6,504	-201	-122	-87.64	-68.33	-
Interest Expenses	-2.8%	105,000	108,000	112,000	109,000	511,000	-	331,000
Earnings Before Taxes	-	-	-	-	-	-32,021,000	-	-
EBT Margin	0%	-2,078	-2,078	-211	-128	-92.01	-71.74	-
Net Income	64.0%	-17,252,000	-47,856,000	-30,389,000	-26,908,000	-32,021,000	-	-16,465,000
Net Income Margin	17.1%	-1,723	-2,078	-211	-128	-92.01	-71.74	-
Free Cashflow	27.3%	-11,076,000	-15,232,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-22.9%	44.00	57.00	71.00	86.00	106	123	137	148	167	135	50.00
Current Assets	-28.3%	33.00	46.00	60.00	73.00	94.00	108	122	133	154	104	36.00
Cash Equivalents	-71.7%	5.00	17.00	37.00	23.00	33.00	19.00	113	125	145	89.00	31.00
Net PPE	-0.4%	11.00	11.00	12.00	12.00	13.00	13.00	13.00	13.00	12.00	11.00	12.00
Liabilities	-8.5%	31.00	34.00	36.00	39.00	44.00	43.00	40.00	35.00	38.00	41.00	75.00
Current Liabilities	-18.3%	18.00	22.00	24.00	26.00	31.00	32.00	29.00	24.00	27.00	31.00	39.00
Shareholder's Equity	-43.4%	13.00	24.00	35.00	46.00	62.00	80.00	97.00	113	129	-	-
Retained Earnings	-3.2%	-361	-350	-337	-323	-304	-284	-265	-247	-229	-181	-92.31
Additional Paid-In Capital	0.3%	375	374	372	369	367	364	362	360	358	24.00	5.00
Shares Outstanding	0.2%	127	126	126	126	126	126	126	-	-	68,668	-
Float	-	-	-	156	-	-	-	95.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	10.3%	-11,838	-13,191	-12,109	-20,100	-14,477	-11,400	-10,537	-19,514	-13,964	-21,074	-17,711	-28,241	-	-
Share Based Compensation	-38.9%	1,081	1,769	2,433	2,225	2,353	2,357	1,826	2,178	24,708	1,462	-	-	-	-
Cashflow From Investing	93.3%	-407	-6,099	26,610	8,740	27,208	-80,348	-539	-713	-1,268	-	-	-	-	-
Cashflow From Financing	17.4%	-313	-379	126	-574	-109	-78.00	6.00	14.00	70,859	-349	79,377	46,280	-	-

VAXX Income Statement

2023-12-31

Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 35,899	$ 47,627
General and administrative	22,386	28,352
Total operating expenses	58,285	75,979
Loss from operations	(58,285)	(75,979)
Other (income) expense:
Interest and other expense	696	514
Interest and other income	(2,090)	(1,259)
(Gain) loss on foreign currency translation, net	43	(12)
Other (income)	(1,351)	(757)
Loss before income taxes	(56,934)	(75,222)
Net loss	$ (56,934)	$ (75,222)
Net loss per share, basic	$ (0.45)	$ (0.60)
Net loss per share, diluted	$ (0.45)	$ (0.60)
Weighted average common shares outstanding, basic	126,508,917	125,939,050
Weighted average common shares outstanding, diluted	126,508,917	125,939,050
Other comprehensive loss:
Unrealized loss (gain) on investments	$ (205)	$ 197
Other comprehensive loss (income)	(205)	197
Comprehensive loss	$ (56,729)	$ (75,419)

VAXX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,931	$ 33,475
Short-term investments	25,464	53,352
Restricted cash	105	1,095
Prepaid expenses and other current assets	2,316	5,551
Total current assets	33,230	93,887
Property and equipment, net	11,081	12,512
Total assets	44,311	106,399
Current liabilities:
Accrued expenses and other current liabilities	3,341	11,370
Total current liabilities	17,605	30,941
Other liabilities:
Other long-term liabilities	35	236
Total liabilities	30,902	44,222
Commitments and contingencies (Note 14)
Stockholders equity:
Additional paid-in capital	374,760	366,799
Accumulated other comprehensive income (loss)	8	(197)
Accumulated deficit	(361,637)	(304,703)
Total stockholders' equity	13,409	62,177
Total liabilities and stockholders' equity	44,311	106,399
Nonrelated Party [Member]
Current liabilities:
Accounts payable	1,783	5,295
Notes payable	406	391
Other liabilities:
Notes payable, net of current portion	9,527	9,933
Related Party [Member]
Current assets:
Amounts due	414	414
Current liabilities:
Accounts payable	10,575	12,772
Notes payable	1,500	1,113
Other liabilities:
Notes payable, net of current portion	3,735	3,112
Class A Common Stock [Member]
Stockholders equity:
Common stock, $0.0001 par value	278	278
Class B Common Stock [Member]
Stockholders equity:
Common stock, $0.0001 par value	$ 0	$ 0

About Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

CEO	Ms. Mei Mei Hu J.D.
WEBSITE	vaxxinity.com
INDUSTRY	Biotechnology
EMPLOYEES	87

Vaxxinity, Inc. Frequently Asked Questions

What is the ticker symbol for Vaxxinity, Inc.? What does VAXX stand for in stocks?

VAXX is the stock ticker symbol of Vaxxinity, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxxinity, Inc. (VAXX)?

As of Fri Apr 26 2024, market cap of Vaxxinity, Inc. is 15.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VAXX stock?

You can check VAXX's fair value in chart for subscribers.

What is the fair value of VAXX stock?

You can check VAXX's fair value in chart for subscribers. The fair value of Vaxxinity, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaxxinity, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VAXX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaxxinity, Inc. a good stock to buy?

The fair value guage provides a quick view whether VAXX is over valued or under valued. Whether Vaxxinity, Inc. is cheap or expensive depends on the assumptions which impact Vaxxinity, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VAXX.

What is Vaxxinity, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, VAXX's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 1.32 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VAXX PE ratio will change depending on the future growth rate expectations of investors.